FDA Approval Summary: Alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer
Preeti Narayan, Tatiana M. Prowell, Jennifer J Gao, Laura L. Fernandes, Emily Li, Xiling Jiang, Junshan Qiu, Jianghong Fan, Pengfei Song, Jingyu Yu, Xinyuan Zhang, Bellinda L. King-Kallimanis, Wei Chen, Tiffany K. Ricks, Yutao Gong, Xing Wang, Katherine Windsor, Steve Y Rhieu, Gerlie Gieser, Anamitro Banerjee, Xiaohong Chen, Francisca Reyes Turcu, Deb K Chatterjee, Anand Pathak, Jeffrey Seidman, Soma Ghosh, Reena Philip, Kirsten B. Goldberg, Paul G. Kluetz, Shenghui Tang, Laleh Amiri-Kordestani, Marc R. Theoret, Richard Pazdur, Julia A Beaver
Clinical Cancer Research Jan 2020, clincanres.3652.2020; DOI: 10.1158/1078-0432.CCR-20-3652